^ 1.01.1Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab. Rev. 2009, 41 (4): 573–643. PMID 19645588. doi:10.1080/03602530903118729.
延伸閱讀
Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 1998, 28 (12): 1129–65. PMID 9890157. doi:10.1080/004982598238868.
Wolf CR, Smith G. Cytochrome P450 CYP2D6. IARC Sci. Publ. 1999, (148): 209–29. PMID 10493260.
Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003, 43 (1): 149–73. PMID 12171978. doi:10.1146/annurev.pharmtox.43.100901.140251.
Lilienfeld S. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002, 8 (2): 159–76. PMID 12177686. doi:10.1111/j.1527-3458.2002.tb00221.x.
Yu AM, Idle JR, Gonzalez FJ. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab. Rev. 2004, 36 (2): 243–77. PMID 15237854. doi:10.1081/DMR-120034000.
Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Earl HM, Dunning AM, Pharoah PD, Caldas C. CYP2D6 gene variants and their association with breast cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 2011, 20 (6): 1255–8. PMID 21527579. doi:10.1158/1055-9965.EPI-11-0321.